Page 108 - JCBP-3-1

Journal of Clinical and
Basic Psychosomatics Serotonin syndrome unexpected medication

doi: 10.3389/fphar.2019.01327 18. Li L, Mi Q. Serotonin syndrome from duloxetine
monotherapy: A case report. Cureus. 2023;15(6):e40933.
13. Gillman PK. New data on metaxalone (Skelaxin) and
serotonin toxicity (serotonin syndrome): Warning of doi: 10.7759/cureus.40933
potential for fatalities if combined with serotonin re-uptake 19. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion
inhibitors. Psycho Trop Commentaries. 2018;6:22-32. induced serotonin syndrome: A case report. J Med Toxicol.
14. King Pharmaceuticals, Inc. Skelaxin (Metaxalone) Tablets: 2010;6(2):168-171.
Prescribing Information (Rev. March 2018). U.S. Food and doi: 10.1007/s13181-010-0021-x
Drug Administration; 2018. Available from: https://www.
fda.gov/drugsatfda [Last accessed on 2024 Jul 21]. 20. Naranjo CA, Busto U, Sellers EM, et al. A method for
estimating the probability of adverse drug reactions. Clin
15. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: Pharmacol Ther. 1981;30(2):239-245.
Clinical pharmacokinetics and drug interactions. Clin
Pharmacokinet. 2011;50(5):281-294. doi: 10.1038/clpt.1981.154
doi: 10.2165/11539240-000000000-00000 21. Möller HJ, Seemüller F, Schennach-Wolff R, Stübner S,
Rüther E, Grohmann R. History, background, concepts
16. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 and current use of comedication and polypharmacy
activity by bupropion. J Clin Psychopharmacol. 25(3): in psychiatry. Int J Neuropsychopharmacol. 2014;17(7):
226-229. 983-996.
doi: 10.1097/01.jcp.0000162805.46453.e3 doi: 10.1017/S1461145713000837
17. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo 22. Mikkelsen N, Damkier P, Pedersen SA. Serotonin
evaluations of cytochrome P450 1A2 interactions with syndrome-A focused review. Basic Clin Pharmacol Toxicol.
duloxetine. Clin Pharmacokinet. 2008;47(3):191-202. 2023;133(2):124-129.
doi: 10.2165/00003088-200847030-00005 doi: 10.1111/bcpt.13912

Volume 3 Issue 1 (2025) 102 doi: 10.36922/jcbp.4490